FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Melanotan I

Afamelanotide / Scenesse / MT-1 / NDP-alpha-MSH

Beauty & Skincare

Melanotan I (afamelanotide) is a synthetic 13-amino acid linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) that selectively agonizes the melanocortin-1 receptor (MC1R) to stimulate eumelanin production in the skin. It is FDA-approved under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike its counterpart Melanotan II, afamelanotide has a more selective receptor profile with significantly fewer systemic side effects.

작용 메커니즘

Synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). Binds melanocortin-1 receptor (MC1R) on melanocytes, stimulating eumelanin production and distribution. Produces gradual, UV-independent tanning. Does not significantly affect sexual function (unlike MT-II).

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 0.5-1mg daily via subcutaneous injection for 10-14 days as a loading phase, then 0.5mg 2-3 times weekly for maintenance. Some UV exposure enhances tanning response.

연구 노트

Clinical Research Status

Afamelanotide received FDA approval in October 2019 and EMA approval in 2014 for erythropoietic protoporphyria, making it one of the few melanocortin peptides to achieve regulatory approval. Additional clinical trials have investigated its potential in vitiligo (to enhance repigmentation when combined with UV therapy), polymorphous light eruption, and solar urticaria. Research into its photoprotective properties for skin cancer prevention in organ transplant recipients has also been explored in Phase II studies.

Key Published Findings

The pivotal Phase III trial (CUV039) demonstrated that afamelanotide significantly increased pain-free time in sunlight for EPP patients compared to placebo, with a median increase of approximately 70 hours over a 6-month period. Vitiligo studies show enhanced and accelerated repigmentation when afamelanotide implants are combined with narrowband UVB phototherapy compared to phototherapy alone. Mechanistic research confirms that MC1R activation by afamelanotide triggers eumelanin synthesis through the cAMP/PKA pathway without requiring UV exposure.

Safety Profile

The most common adverse effects include nausea, headache, and darkening of pre-existing nevi (moles), with injection site reactions at the implant location. Unlike Melanotan II, afamelanotide does not typically cause facial flushing, nausea at therapeutic doses, or sexual side effects due to its selectivity for MC1R over MC3R/MC4R. Long-term surveillance data spanning over a decade of use has not identified increased melanoma risk, though regular dermatological monitoring is recommended.

Comparison to Related Compounds

Melanotan I is a linear peptide with high MC1R selectivity, while Melanotan II is a cyclic heptapeptide with broad activity across MC1R, MC3R, MC4R, and MC5R receptors, explaining MT-II's wider side effect profile including appetite suppression and sexual effects. Afamelanotide produces more gradual, natural-appearing tanning compared to the rapid but sometimes uneven pigmentation seen with Melanotan II. The FDA-approved implant formulation provides sustained release over approximately 60 days, whereas MT-II requires frequent subcutaneous injections.

Community Observations

Users seeking cosmetic tanning generally prefer Melanotan II for its faster onset and additional effects, while those specifically interested in photoprotection without sexual side effects may prefer Melanotan I. The FDA-approved implant form (Scenesse) is extremely expensive and limited to EPP patients, leading some users to source research-grade afamelanotide powder for self-administration. Community reports suggest more natural and even tanning compared to MT-II, but with a slower onset typically requiring 2-4 weeks before visible pigmentation changes.

반감기

~30 minutes

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 24 months. Protect from light.

재조성된 상태

Refrigerate 2-8C. Use within 30 days.

미국 법적 상태

FDA-approved for EPP only (Rx - Scenesse)

또는 알려진 이름으로

AfamelanotideScenesseMT-1NDP-alpha-MSH

자주 묻는 질문

Melanotan I란 무엇인가요?

Melanotan I (afamelanotide) is a synthetic 13-amino acid linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) that selectively agonizes the melanocortin-1 receptor (MC1R) to stimulate eumelanin production in the skin. It is FDA-approved under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike its counterpart Melanotan II, afamelanotide has a more selective receptor profile with significantly fewer systemic side effects.

Melanotan I는 어떻게 작용하나요?

Synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). Binds melanocortin-1 receptor (MC1R) on melanocytes, stimulating eumelanin production and distribution. Produces gradual, UV-independent tanning. Does not significantly affect sexual function (unlike MT-II).

Melanotan I의 미국 규제 현황은 어떤가요?

FDA-approved for EPP only (Rx - Scenesse)

Melanotan I의 반감기는 얼마인가요?

~30 minutes

Melanotan I의 다른 이름은 무엇인가요?

Afamelanotide, Scenesse, MT-1, NDP-alpha-MSH

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기